Dicerna Pharmaceuticals, Inc. (DRNA): Price and Financial Metrics


Dicerna Pharmaceuticals, Inc. (DRNA)

Today's Latest Price: $24.89 USD

0.50 (-1.97%)

Updated Jul 10 4:00pm

Add DRNA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

DRNA Stock Summary

  • DRNA's price/sales ratio is 33.56; that's higher than the P/S ratio of 94.89% of US stocks.
  • With a year-over-year growth in debt of 1,388.97%, Dicerna Pharmaceuticals Inc's debt growth rate surpasses 98.43% of about US stocks.
  • As for revenue growth, note that DRNA's revenue has grown 608.52% over the past 12 months; that beats the revenue growth of 98.86% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Dicerna Pharmaceuticals Inc are SRRK, TBIO, CKPT, AGIO, and BPMC.
  • Visit DRNA's SEC page to see the company's official filings. To visit the company's web site, go to www.dicerna.com.
DRNA Daily Price Range
DRNA 52-Week Price Range

DRNA Stock Price Chart Technical Analysis Charts


DRNA Price/Volume Stats

Current price $24.89 52-week high $27.68
Prev. close $25.39 52-week low $11.75
Day low $24.82 Volume 310,874
Day high $25.79 Avg. volume 692,033
50-day MA $22.69 Dividend yield N/A
200-day MA $20.44 Market Cap 1.84B

Dicerna Pharmaceuticals, Inc. (DRNA) Company Bio


Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company is using its proprietary RNA interference technology platform to build a broad pipeline in these therapeutic areas. The company was founded in 2006 and is based in Cambridge, Massachusetts.


DRNA Latest News Stream


Event/TimeNews Detail
Loading, please wait...

DRNA Latest Social Stream


Loading social stream, please wait...

View Full DRNA Social Stream

Latest DRNA News From Around the Web

Below are the latest news stories about Dicerna Pharmaceuticals Inc that investors may wish to consider to help them evaluate DRNA as an investment opportunity.

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among 15 employees.

Yahoo | July 1, 2020

Dicerna nabs Rare Pediatric Disease tag for nedosiran for primary hyperoxaluria

The FDA has granted rare pediatric disease designation to Dicerna Pharmaceuticals' (DRNA) nedosiran, an investigational RNAi therapy being developed as a once-monthly treatment for primary hyperoxaluria, a family of ultra-rare, life-threatening genetic disorders that cause complications in the kidneys.Rare Pediatric Disease Designation provides for the issuance of a rare pediatric disease...

Seeking Alpha | June 18, 2020

Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria

Dicerna announced that the U.S. FDA has granted rare pediatric disease designation for nedosiran, which is in development for PH types 1, 2 and 3.

Yahoo | June 18, 2020

Hedge Funds Aren’t Crazy About Dicerna Pharmaceuticals Inc (DRNA) Anymore

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | June 15, 2020

2 Top Small-Cap Stocks to Buy Right Now

On June 10, Chair of the Federal Reserve Jerome Powell cautioned that an economic recovery won't be quick or painless. Considering Wall Street had already priced in a relatively optimistic recovery scenario, it's not too surprising Powell's comments popped the stock market's rally. It doesn't help that a handful of states are reporting case and hospitalization figures that suggest a second wave of coronavirus infections -- and subsequently, more restrictions on movement -- could be on the horizon.

Yahoo | June 12, 2020

Read More 'DRNA' Stories Here

DRNA Price Returns

1-mo 26.28%
3-mo N/A
6-mo 24.45%
1-year 75.28%
3-year 660.00%
5-year 85.61%
YTD 12.98%
2019 106.08%
2018 18.38%
2017 213.54%
2016 -75.74%
2015 -27.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8826 seconds.